India

COVAXIN shows interim efficacy of 81% in phase 3 clinical trials


Image Source : FILE PHOTO

COVAXIN shows interim efficacy of 81 per cent in phase 3 clinical results, says Bharat Biotech.

India’s indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.

Covaxin is India’s totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

The vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.

Latest India News





Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button